Drug Trial Radar · NCT05798611
Study of ART0380 in Patients With Biologically Selected Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
36
Actual
Start
Sep 6, 2023
Primary completion
Nov 15, 2024
Study completion May 27, 2025
Sponsor
- Lead sponsor
- Artios Pharma LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 4, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This interventional study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict for sensitivity to inhibition of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR).
Conditions
- Advanced Solid Tumor
- Recurrent Endometrial Cancer
- Metastatic Cancer
Interventions
ART0380Drug
Randomized patients will orally receive ART0380.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Until disease progression (Every 6 weeks from randomization Upto 2 Years)
Locations
15 sites in 3 countries. Site status is shown where the registry gives one.
University of California Los Angeles (UCLA)
Los Angeles, California
The University of Chicago
Chicago, Illinois
Dana Farber Cancer Center
Boston, Massachusetts
Northwell Health R.J. Zuckerberg Cancer Center
Lake Success, New York
Memorial Sloan Kettering Cancer Center (MSKCC) - Memorial Hospital - Oncology
New York, New York
University of Oklahoma/Sarah Cannon Research Institute
Oklahoma City, Oklahoma
Western Pennsylvania Hospital
Pittsburgh, Pennsylvania
Women and Infants Hospital
Providence, Rhode Island
Institut de Cancérologie de l'Ouest
Angers, NAP, France
Centre Francois Baclesse - Service d'Oncologie médicale
Caen, NAP, France
Hopital Cochin Saint Vincent De Paul
Paris, NAP, France
Hopital Lyon Sud
Pierre-Bénite, NAP, France
Centre Hospitalier Universitaire De Poitiers
Poitiers, NAP, France
Fundación Instituto Valenciano De Oncología
Valencia, Spain
Hospital Universitario De Jaén
Jaén, Andalusia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.